Bibliography for ICM6011: Brain and Mind, Disorders of Supraspinal Systems

[1]
T. Sudhof, ‘The synaptic vesicle cycle: a cascade of protein-protein interactions’, Nature (London), 6AD [Online]. Available: http://wt3cf4et2l.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info:sid/summon.serialssolutions.com&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The+synaptic+vesicle+cycle%3A+a+cascade+of+protein-protein+interactions&rft.jtitle=Nature&rft.au=Sudhof%2C+Thomas+C&rft.date=1995-06-22&rft.pub=Nature+Publishing+Group&rft.issn=0028-0836&rft.eissn=1476-4687&rft.volume=375&rft.issue=6533&rft.spage=645&rft.externalDBID=BSHEE&rft.externalDocID=17277217&paramdict=en-US

[2]
‘The synaptic vesicle cycle: a cascade of protein-protein interactions’. [Online]. Available: http://www.nature.com/nature/journal/v375/n6533/pdf/375645a0.pdf

[3]
K. Chen et al., ‘Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures’, Journal of Neuroscience, vol. 27, no. 1, pp. 46–58, Jan. 2007, doi: 10.1523/JNEUROSCI.3966-06.2007.

[4]
Krisztina, F. Massa, M. Egertová, and M. Eder, ‘The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0896627306005460

[5]
R. Nyilas, B. Dudok, and G. M. Urbán, ‘Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals’ [Online]. Available: http://www.jneurosci.org.ezproxy.library.qmul.ac.uk/content/28/5/1058

[6]
M. Solinas, S. R. Goldberg, and D. Piomelli, ‘The endocannabinoid system in brain reward processes’, British Journal of Pharmacology, vol. 154, no. 2, pp. 369–383, Jan. 2009, doi: 10.1038/bjp.2008.130.

[7]
‘The endocannabinoid system in brain reward processes’. [Online]. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442437/pdf/bjp2008130a.pdf

[8]
T. Arendt, ‘Alzheimer’s disease as a disorder of mechanisms underlying structural brain self-organization’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0306452200005169

[9]
T. Arendt, ‘Alzheimer’s disease as a disorder of mechanisms underlying structural brain self-organization’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0306452200005169

[10]
I. D. Dominguez and B. D. Strooper, ‘Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer’s disease’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0165614702020382

[11]
E. Bezard, J. M. Brotchie, and C. E. Gross, ‘Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies : Article : Nature Reviews Neuroscience’ [Online]. Available: http://www.nature.com.ezproxy.library.qmul.ac.uk/nrn/journal/v2/n8/full/nrn0801_577a.html

[12]
C. T. McMurray, ‘Huntington’s disease: new hope for therapeutics’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0166223601000066

[13]
J. De Keyser, G. Sulter, and P. G. Luiten, ‘Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0166223699014630

[14]
H. L. Zhu, W. Q. Luo, and H. Wang, ‘Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0306452208014024

[15]
L. Fredrik Jarskog, S. Miyamoto, and J. A. Lieberman, ‘Schizophrenia: New Pathological Insights and Therapies - Annual Review of Medicine, 58(1):49’ [Online]. Available: http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/abs/10.1146/annurev.med.58.060904.084114

[16]
S. Iritani, ‘Neuropathology of schizophrenia: A mini review’, Neuropathology, vol. 27, no. 6, pp. 604–608, Dec. 2007, doi: 10.1111/j.1440-1789.2007.00798.x.

[17]
M. LARUELLE, L. S. KEGELES, and A. ABI-DARGHAM, ‘Glutamate, Dopamine, and Schizophrenia’, Annals of the New York Academy of Sciences, vol. 1003, no. 1, pp. 138–158, Nov. 2003, doi: 10.1196/annals.1300.063.

[18]
E. F. Torrey, B. M. Barci, M. J. Webster, J. J. Bartko, J. H. Meador-Woodruff, and M. B. Knable, ‘Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains’, Biological Psychiatry, vol. 57, no. 3, pp. 252–260, Feb. 2005, doi: 10.1016/j.biopsych.2004.10.019.

[19]
W. Löscher, ‘Current status and future directions in the pharmacotherapy of epilepsy’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S016561470001974X

[20]
J. C. Mulley, I. E. Scheffer, S. Petrou, and S. F. Berkovic, ‘Channelopathies as a genetic cause of epilepsy.’ [Online]. Available: http://ovidsp.tx.ovid.com.ezproxy.library.qmul.ac.uk/sp-3.16.0a/ovidweb.cgi?&S=OLHFFPBBICDDHECMNCKKKBIBBLDIAA00&Link+Set=jb.search.31%7c1%7csl_10

[21]
J. C. Mulley, I. E. Scheffer, S. Petrou, and S. F. Berkovic, ‘Channelopathies as a genetic cause of epilepsy’. [Online]. Available: http://ovidsp.tx.ovid.com.ezproxy.library.qmul.ac.uk/sp-3.16.0a/ovidweb.cgi?WebLinkFrameset=1&S=OLHFFPBBICDDHECMNCKKKBIBBLDIAA00&returnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cjb.search.31.32%257c0%257c00019052-200304000-00009%26S%3dOLHFFPBBICDDHECMNCKKKBIBBLDIAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCIBKBCMIC00%2ffs004%2fovft%2flive%2fgv006%2f00019052%2f00019052-200304000-00009.pdf&filename=Channelopathies+as+a+genetic+cause+of+epilepsy.&pdf_key=FPDDNCIBKBCMIC00&pdf_index=/fs004/ovft/live/gv006/00019052/00019052-200304000-00009&D=ovft

[22]
M. Maalouf, J. M. Rho, and M. P. Mattson, ‘The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0165017308001045

[23]
B. Schmitz, G. Montouris, B. Schäuble, and S. Caleo, ‘Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control’, Epilepsia, vol. 51, no. 11, pp. 2231–2240, Nov. 2010, doi: 10.1111/j.1528-1167.2010.02759.x.

[24]
E. J. Nestler, ‘Is there a common molecular pathway for addiction? : Article : Nature Neuroscience’ [Online]. Available: http://www.nature.com.ezproxy.library.qmul.ac.uk/neuro/journal/v8/n11/full/nn1578.html

[25]
C. Dackis and C. O’Brien, ‘Neurobiology of addiction: treatment and public policy ramifications : Article : Nature Neuroscience’ [Online]. Available: http://www.nature.com.ezproxy.library.qmul.ac.uk/neuro/journal/v8/n11/full/nn1105-1431.html

[26]
N. D. Volkow, J. S. Fowler, and G.-J. Wang, ‘The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies’ [Online]. Available: http://www.sciencedirect.com.ezproxy.library.qmul.ac.uk/science/article/pii/S0028390804002163

Bibliography for ICM6011: Brain and Mind, Disorders of Supraspinal Systems BETA